Postpartum timing of teriparatide initiation and BMD response in pregnancy- and lactation-associated osteoporosis: an observational study.

What Was Tested

This observational study looks at Teriparatide.

Optimal management for PLO is uncertain.

Teriparatide is the most common medication investigated.

Since treatment may overlap with the skeletally dynamic postweaning recovery period, the researchers hypothesized that postpartum treatment timing would affect BMD response to teriparatide.

Why It Was Studied

This observational study of teriparatide-treated PLO documents a substantial effect of postpartum treatment timing on BMD response.

This study provides important data to inform treatment response expectations in clinical care of teriparatide-treated PLO.

Who Took Part

According to the abstract, 31 women were involved.

By PubMed's age tags, the people studied were adults, women only.

Within their PLO Registry, BMD was assessed at baseline, 6M, and 12M in 31 women with PLO who initiated teriparatide either < 12M postpartum (EarlyRx, n = 10, initiation 7 ± 3 M postpartum) or ≥ 12M postpartum (DelayedRx, n = 21, initiation 36 ± 29 M postpartum).

How the Study Was Run

Groups were similar in terms of age, BMI, parity, number of fractures, and breastfeeding duration.

What Was Measured

PubMed files the paper under topics including Teriparatide, Bone Density, Bone Density Conservation Agents, Osteoporosis, Pregnancy Complications, Lactation and Postpartum Period.

Author keywords: Pregnancy- and lactation-associated osteoporosis and Premenopausal osteoporosis.

What This Means in Plain Language

This is an observational study of Teriparatide in 31 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Teriparatide compound page, all human trials.